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Abstract: Colorectal cancer (CRC) is the second most common human malignancy in women and the third in men, accounting
for approximately 8% of cancer-related deaths and 1.3 million newly diagnosed cases annually worldwide. CRC cell lines differ in
morphological features, growth rate, and their genetic alterations, implicating the extent of variability among the lines. The goal of
the current study was to investigate the phenotypes of CRC lines related to NADPH oxidase (NOX) activity and expression of NOX2
subunits in response to fluoropyrimidines. NOX activity in response to 5’-fluoro-2’-deoxyuridine (FdUrd) and VAS2780 was measured
in CRC cell lines. Cells were treated with FdUrd in order to determine apoptotic cell death and mRNA expressions of NOX2 cytoplasmic
subunits. We find that both basal and drug-induced NOX activity differ in the lines. Similarly, drug-mediated apoptotic indices vary in
the cell lines at basal levels. Among NOX1 and NOX2 subunits, only NOX2 accessory subunits, p67phox, p40phox, and p47phox, differ
in the lines. Our results show that CRC cells have diverse oxidative background and their oxidative response to anticancer drugs vary,
while they all exhibit increases in NOX activity.
Key words: NADPH oxidase, fluoropyrimidines, oxidative stress, CRC cells

1. Introduction
Colorectal cancer (CRC) is the third most common
cancer worldwide in males and the disease rate is the
highest in developed countries, including the US,
Australia, Canada, and Europe. It accounts for 8% to 9%
of the estimated cancer deaths in the US in 2015 (Siegel
et al., 2015). Treatment of CRC depends upon the degree
of progression of the cancer and it can be curative if
caught at an early stage (Cunningham et al., 2010; Stein
et al., 2011). Survival rate (5 years) has not changed
with the recent advances and chemotherapy is still the
mainstay of treatment (Lucas et al., 2011; Platell et al.,
2011). Fluoropyrimidines, in particular, FUra and its
nucleoside analogue 5’-fluoro-2’-deoxyuridine (FdUrd),
are widely used agents and remain a major component
of many standard regimens for various cancer types
(Sotos et al., 1994; Milano et al., 2004; Soong and Diasio,
2005; Soong et al., 2008). FUra and FdUrd inhibit
thymidylate synthase (TS), which blocks thymidylate
(dTMP) production (Berger and Berger, 2006; Wyatt
and Wilson, 2009) and leads to genome damage through
misincorporation of uracil into DNA, and shuts off DNA
synthesis and repair, triggering apoptosis (Danenberg,
1977; Spears et al., 1988; Krokan et al., 2002; Longley et
al., 2003). It has been suggested that generation of reactive
* Correspondence: ufuk.ozer@dicle.edu.tr

oxygen species (ROS) is one of the consequences of TS
inhibition. ROS production is increased by FUra, and the
inhibition of ROS reverses its cytotoxicity (Ueta et al.,
1999; Hwang et al., 2001; Laurent et al., 2005; Alexandre
et al., 2006, Hwang et al., 2007; Shibata et al., 2008). As a
result of drug treatment, ROS are released and partially
trigger apoptosis in cancer cells (Gallego et al., 2008).
Accordingly, a significant strategy involves modulation
of oxidative stress in cancer cells in order to sensitize
them to anticancer drugs and generate novel protocols
for improved clinical responses (O’Dwyer et al., 1996;
Bougnoux et al., 2009). It is known that the activity of ROS
generating enzymes like NADPH oxidases is increased to
kill cancer cells (Lambeth, 2004; Kumar et al., 2008). The
family of NADPH oxidases (NOX); NOX1-5 and dual
oxidases (Duox), Duox1 and Duox2 produce ROS as their
primary and sole function (Lambeth, 2004; Bedard and
Krause, 2007; Altenhöfer et al., 2012). NOX1 and NOX2
are potentially important targets of TS inhibitors that
induce ROS formation, since they are highly expressed
in colon tissue (Hwang et al., 2001; Juhasz et al., 2009).
We have previously reported that augmentation of NOX2
activity via induction of p67phox mRNA expression is
the proximate cause of oxidative cell death in HCT116
cells (Ozer et al., 2015).
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CRC is a malignant disease that results from
accumulation of genetic and epigenetic alterations that lead
to derangements in cell proliferation, and differentiation,
giving rise to transformation of normal colonic epithelium to
colon adenocarcinoma (Vogelstein et al., 1988). Established
and characterized cell lines were classified into different
groups based on their morphological features, growth rate,
and other functional parameters, implicating a broad range
of systemic heterogeneity and drug response (Leibovitz et
al., 1976; Brattain et al., 1981; McBain et al., 1984; Ribas et
al., 2003; Flatmark et al., 2004; de Anta et al., 2006).
Heterogeneity is also apparent in apoptosis of different
colon cancer cells and is a major drawback in identifying
treatments (Fidler and Goste, 1985). Heterogeneity in
apoptosis originates from variations in protein expression
and protein interactions in different colon cancer cells
(Schmid et al., 2012). In spite of these interesting findings,
understanding of how these cells indicate diverse response
to drugs is still lacking. In the present study, we examined
levels of NOX induced-oxidative stress and -apoptotic
cell death in response to TS inhibitors in different colon
cancer cells. We found variations regarding NOX activity,
expression of NOX2 subunits, and the role of NOX in
apoptotic response to TS inhibitors.
2. Materials and methods
2.1. Materials
FUra and FdUrd were from Sigma-Aldrich Co. (St. Louis,
MO, USA). NADPH was purchased from Calbiochem/EMD
Biosciences (San Diego, CA, USA). Lucigenin and VAS2870 were provided by Enzo Life Sciences Inc. (Plymouth
Meeting, PA, USA). Paraformaldehyde was from Alfa
Aesar (Ward Hill, MA, USA). Oligonucleotides were from
Integrated DNA Technologies Inc. (Coralville, IA, USA).
2.2. Cell culture
Human colon tumor cell lines HCT116 (originally obtained
from Dr. Michael G. Brattain), SW480, HCT15, DLD1, LoVo, MOSER, and LS180 (obtained from American
Type Culture Collection, Manassas, VA, USA) were grown
in RPMI-1640 medium (Cellgro, Manassas, VA, USA)
supplemented with 10% heat-activated fetal bovine serum
(Atlanta Biologicals, Flowery Branch, GA, USA) at 37 °C
in a humidified 5% CO2 atmosphere.
2.3. Measurement of apoptotic cell death
TS inhibitors and inhibitory agents were applied to cells
at the indicated concentrations and times. Apoptotic
indices were determined by TUNEL assays, performed
using the In Situ Cell Death Detection Kit, POD (Roche
Applied Science, Indianapolis, IN, USA). Cells were
stained according to the manufacturer’s instructions,
counterstained with hematoxylin, and viewed under a
light microscope at 400× magnification. Pictures from
each treatment were taken with camera installed on top of
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the microscope. Apoptotic nuclei were counted manually,
based on staining and morphology, and the apoptotic
index was calculated as the ratio of apoptotic/total cells.
In each determination, at least 1000 cells from several
microscopic fields were counted.
2.4. NADPH oxidase assay
For each reaction, 105 cells were suspended in 500 μL of
reaction buffer [50 mM phosphate buffer (pH 7.0), 1 mM
EGTA, 150 mM sucrose]. NADPH oxidase activity was
detected by lucigenin-derived chemiluminescence with 100
µM NADPH as substrate and 5 µM lucigenin. Cells were
incubated at 37 °C for 10 min. Chemiluminescence was
measured using a luminometer (Promega, Madison, WI,
USA) and expressed as arbitrary light units per 105 cells.
2.5. RNA extraction and RT-PCR
Total RNA was isolated using RNeasy Mini Kit (Qiagen,
MD, USA) with the addition of RNase Free DNase
(Qiagen, Hilden, Germany) to eliminate contaminating
genomic DNA. The RNA concentration was determined
by measuring the absorbance at 260 nm and 280 nm
(NanoDrop ND-1000 Spectrophotometer, Thermo
Fisher Scientific, USA). For each reaction, 1 µg of
RNA was reverse transcribed using an IScript cDNA
synthesis kit (Biorad, Hercules, CA, USA) according to
the manufacturer’s instructions. For quantitative PCR
(qPCR), cDNA (1 µL) prepared as described above was
amplified using Power SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) according to
the manufacturer’s instructions. The PCR thermal profile
was one cycle at 95 °C for 10 min followed by 40 cycles of
95 °C for 15 s, 50 °C for 15 s, and 72 °C for 40 s using an
Applied Biosystems 7300 Real Time PCR System. Relative
mRNA levels were normalized to GAPDH, and calculated
by the 2−ΔΔCt method. Relative changes in expression of
each gene in response to TS inhibitors were expressed as
fold-induction compared with the basal level of expression
in nontreated cells. Gene-specific primer sets (Integrated
DNA Technologies) used for qPCR are listed in the Table.
Controls with no reverse transcriptase and no template
RNA were used to monitor contamination.
2.6. Western blotting
Cells were lysed in M-PER mammalian protein extraction
reagent (Thermo Scientific, Rockford, IL, USA) and
protein content was determined colorimetrically using
the Bradford assay (Bio-Rad, Hercules, CA, USA) with
BSA as protein standard. Lysates (100 µg) were run on
12.5% Tris/HCl (Bio-Rad), electrophoresed in running
SDS-PAGE buffer, transferred to PVDF membranes,
and probed with anti-p67phox goat polyclonal antibody
(sc7662, C-19, Santa Cruz, Dallas, TX, USA) at a dilution
of 1:200 in 3% nonfat milk in PBS/0.05% Tween for 1 h
at room temperature. The membrane was washed three
times for 10 min with PBS/0.05% Tween before and after
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Table. Sequence of the primers for quantitative RT-PCR.
Genes

Primers (5’ to 3’)

p67phox

sense: 5’- ACCAGAAGCATTAACCGAGAC -3’
antisense: 5’- TTCCCTCGAAGCTGAATCAAG -3’

p47phox

sense: 5’- GCTGGTGGGTCATCAGGAA -3’
antisense: 5’- GCCCCGACTTTTGCAGGTA -3’

p40phox

sense: 5’- GCTTCACCAGCCACTTTGTT -3’
antisense: 5’- TCCTGTTTCACACCCACGTA -3’

GAPDH

sense: 5’- TCCCTGAGCTGAACGGGAAG -3’
antisense: 5’- GGAGGAGTGGGTGTCGCTGT -3’

and MOSER, were treated with 10 µM FdUrd for 24 h,
and NOX activity was measured. HCT116 basal activity
levels were set as 1 and the fold-increase in activity in
other cell lines in the absence and presence of FdUrd was
calculated. Basal levels of NOX activity in these cell lines
range from 1.2- to 4.2-fold. Following FdUrd, the activity
was increased 1.7- to 4.8-fold in lines. MOSER had the
highest basal (4.2-fold) and drug-inducible (4.8-fold, P =
0.0174) activity level among these cells. However, DLD-1
and LoVo cell lines showed low basal (1.2- and 1.6-fold,
respectively) and drug-inducible (2.5-fold, P = 0.025 and
1.7-fold, respectively) activity levels (Figure 1).
In order to verify whether NOX activity was decreased
by a specific NOX inhibitor, VAS-2870, in cell lines, we
examined NOX activity in response to FUra and FdUrd
in human colon cancer cell lines: HCT116, HCT15, and
SW480. NOX activity was induced (P < 0.05) by drugs
for all 3 colon cancer lines; furthermore, the activation of
NOX in all 3 cell types was diminished (P < 0.05) by VAS2870 (Figure 2).

incubation with appropriate secondary antibody for 1
h at room temperature. An ECL kit (GE Healthcare Life
Sciences, Amersham ECL, Pittsburgh, PA, USA) was
used to visualize the antigen–antibody complexes by
chemiluminescence after washing the membrane.
2.7. Statistical analysis
All data were reported as the mean ± SEM. Statistical
significance of the mean for each group was determined
using Student’s t-test. Differences with P ≤ 0.05 were
considered statistically significant.
3. Results
3.1. Human colon cancer cell lines exhibit different levels
of NOX activity
Human colon cancer cell lines show a wide range of
genetic, morphological, and functional heterogeneity
(Leibovitz et al., 1976; Brattain et al., 1981; McBain et al.,
1984). In order to determine whether these cell lines show
variations in NOX activity in response to FdUrd, several,
including HCT116, HCT15, SW480, DLD-1, LoVo,

P
P

f

a

P

Figure 1. NOX activity levels vary in human colon cancer cell lines. HCT116, HCT15, SW480, DLD-1, LoVo, and MOSER cell lines were
grown ± 10 µM FdUrd for 24 h and then were subjected to NOX activity assay. Lucigenin derived chemiluminescence was measured by
luminometer. Relative fold increase was calculated in reference to HCT116 control, which was set as 1. Bars represent fold increase in
chemiluminescence ± SEM from 3 experiments.
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Figure 2. VAS reduces NOX activity increased by drugs in colon cancer cell lines. HCT116, SW480, and HCT15 cells were treated with
both TS inhibitors (10 µM FUra, 10 µM FdUrd) and 10 µM VAS for 24 h. NOX activity was measured by luminometer. Relative fold
increase was calculated in reference to HCT116 control, which was set as 1. Bars represent fold increase of chemiluminescence ± SEM
from 3 experiments.

3.2. Apoptotic response to FdUrd varies in human colon
cancer cells
Heterogeneity arising among tumor cells can lead to
resistance to chemotherapeutic drugs (de Anta et al.,
2006) and may be a significant impediment in effective
chemotherapeutic treatments (Fidler and Goste, 1985).
It has been previously shown that apoptotic protein
expression and interactions differ in colon cancer cells
(Schmid et al., 2012). Thus, we determined if apoptotic
response to FdUrd varies among different colon cancer
cells. In order to test this, HCT116, HCT15, SW480, and
LoVo cells were treated with FdUrd for 24 h, and apoptotic
indices were evaluated by TUNEL assay. We observed that
drug-mediated cells were swelled and apoptotic cells were
dark brown (Figure 3A). It was observed that basal levels of
apoptosis change from cell line to cell line. LoVo exhibited
3-fold higher (P = 0.009) basal levels relative to HCT116
cells and HCT15. Drug-mediated increases in apoptotic
indices were greater in HCT116 and HCT 15 cells (16fold, P = 0.0076 and 14-fold, P = 0.0084) respectively than
SW480 and LoVo cells (8-fold, P = 0.0088 and 6.5-fold, P
= 0.0092), respectively (Figure 3B).
3.3. mRNA expressions of NOX2 accessory subunits,
p67phox, p40phox, and p47phox, differ in human colon
cancer cell lines
It has previously been demonstrated that expression
of NOX isoforms and their accessory subunits varies
in human tumor cells (Juhasz et al., 2009). Given the
variation in NOX activity levels and apoptotic responses in
human colon cancer cells, we determined whether mRNA
levels of NOX2 accessory subunits, p67phox, p40phox,
and p47phox, vary in different colon cancer cells. Cells
were treated with FdUrd for 24 h and expression of the
subunits was assessed by qPCR. Human colon cancer cell
lines (HCT116, HCT15, SW480, DLD-1, LoVo, MOSER,
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and LS180) showed different basal and drug-inducible
mRNA levels for p67phox (Figures 4A). LoVo, MOSER
and LS180 exhibited high basal levels of p67phox (P <
0.05) while SW480 exhibited intermediate levels (P <
0.05). HCT116, HCT15 and DLD-1 expressed low basal
levels of p67phox. FdUrd-induced p67phox levels were
seen in HCT116 and DLD-1, about 23-fold (P = 0.0045)
and 9-fold (P = 0.0076), respectively (Figure 4A). Protein
levels of p67phox subunits in colon cancer cells exhibited
the same trend as seen in its mRNA expression (Figure
4B). Low basal levels of p67phox in several lines could not
be detected by western-blot analysis.
Expression of p40phox was low in HCT15, LoVo, and
MOSER cells compared to HCT116, SW480, DLD-1, and
LS180. FdUrd-induced p40phox levels in HCT15 and
LoVo cells were 8-fold (P = 0.025) and 10-fold (P = 0.021),
respectively. HCT116 and MOSER cells exhibited low
levels of drug-induced p40phox levels while SW480, DLD1, and LS180 expressed intermediate levels (Figure 5).
Basal and drug-inducible mRNA levels of p47phox
also vary among the lines. HCT116 and SW480 showed
similar basal and drug-inducible mRNA levels of p47phox.
Although MOSER and LS180 exhibited similar basal
levels of p47phox, drug-induced levels were unchanged in
MOSER, but were induced 8.5-fold (P = 0.019) in LS180
cells (Figure 6).
4. Discussion
Cancer laboratories establish a large number of human
colorectal cancer cell lines from surgical specimens in
the pathology laboratories. Based on their morphological
features, growth rate, karyotypes, ability to synthesize
carcinoembryonic antigen (CEA), etc., these lines were
classified into different groups (Leibovitz et al., 1976;
McBain et al., 1984). Well-described colon cancer cells
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A

Figure 3. FdUrd diversely induces apoptosis in human colon cancer cells. HCT116, HCT15, SW480, and LoVo cells were grown with
Controlby TUNELFdUrd
andA
without 100 µM FdUrd for 24 h. Extents of apoptosis were determined
assay. A. Cells were photographed at 400×. B.
1000 was calculated in reference to HCT116 control, which was set as 1. Bars represent fold increase of apoptotic indices
Relative fold increase
± SEM from 3 experiments.
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Figure 4. FdUrd
mRNA levels -of p67phox
mRNA
levels of p67phox in total
RNA isolated from HCT116, HCT15, SW480, DLD-1, LoVo, MOSER, and LS180 cultured for 24 h ± 10 µM FdUrd. Relative fold increase
was calculated in reference to HCT116 control, which was set as 1. GAPDH was tested as a loading control. Bars represent an average of fold
HCT116
HCT15levels of p67phox
SW480 were measured
DLD-1 for the lines
LoVo
MOSER
increase ± SEM from 3 experiments.
B. Protein
cultured for 24
h ± 10 µM FdUrd.
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Figure 5. mRNA levels of p40phox vary in human colon cancer cell lines. qPCR was used to measure mRNA levels of p40phox in total
RNA isolated from HCT116, HCT15, SW480, DLD-1, LoVo, MOSER, and LS180 cultured for 24 h ± 10 µM FdUrd. GAPDH was tested
as a loading control. Relative fold increase was calculated in reference to HCT116 control, which was set as 1. Bars represent an average
of fold increase ± SEM from 3 experiments.
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Figure 6. mRNA levels of p47phox vary in human colon cancer cells. qPCR was used to measure mRNA levels of p47phox in total RNA
isolated from HCT116, HCT15, SW480, DLD-1, LoVo, MOSER, and LS180 cultured for 24 h ± 10 µM FdUrd. GAPDH was tested as a
loading control. Relative fold increase was calculated in reference to HCT116 control, which was set as 1. Bars represent an average of
fold increase ± SEM from 3 experiments.

characterized in vivo and in vitro with regard to drug
response, genetic abnormalities, expression of cancerassociated genes, etc. display important differences
in tumor growth and metastatic capacity, leading to
heterogeneity, possibly in a clinical relevant manner
(Flatmark et al., 2004). Heterogeneity resulting from
any system in cancer cells may bring about resistance to
chemotherapeutic drugs (de Anta et al., 2006). However,
understanding the mechanism of the heterogeneity creates
an opportunity to increase the efficacy of drugs in the
treatment of tumor cells. It is possible that a number of
biomarkers differing in cell lines might be relevant to
variations. Knowledge augmentation of heterogeneity in
cell lines will lead to improved therapy.
In the present study, we demonstrated that FdUrd
induced apoptosis 6.5- to 16-fold change in human colon
cancer cell lines. These different inductions result from
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variation in basal apoptosis levels of cell lines, reflecting
the heterogeneity in cell lines. Our findings make it clear
that FdUrd induces cell death in all cell lines, but its effects
on their survival vary because of different backgrounds.
We have indicated that increases in NOX activity by TS
inhibitors were in HCT116, SW480, and HCT15 cell lines
and VAS2870 attenuated drug-induced activity (Figure 2).
In order to expand the results, we determined basal and
drug-increased levels of NOX activity in six different cell
lines. Here, we demonstrate that they vary in basal NOX
activity levels, reflecting different backgrounds among
the lines. In response to FdUrd, increases in NOX activity
were profoundly exhibited in most cell lines, with DLD-1
and LoVo showing only slight increases. Thus, cell lines
differ in the oxidative environment and exhibit, in the
presence of fluoropyrimidines, different mechanisms to
modulate it.
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Our results are consistent with earlier studies, which
revealed that human colon cancer cell lines exhibit
different expression levels for NOX genes (Juhasz et al.,
2009). As shown in Figure 4A, p67phox expression in
SW480, LoVo, MOSER, and LS180 is much higher than in
HCT116 while it is lower in DLD-1 and HCT15. Therefore,
drug inducible expression levels of p67phox are hardly
seen in SW480 and LoVo. However, p67phox expression
levels were further induced by FdUrd in MOSER cells
despite very high basal expression levels. These results are
not consistent with basal NOX activity levels in cell lines
(Figure 1), indicating the importance of other subunits
in the activation. Then we looked at expression of other
subunits like p40phox and p47phox. Basal p40phox
expression was much lower in HCT15, LoVo, and MOSER
cells compared to HCT116 cells. FdUrd-induced p40phox
levels are easily seen in all cell lines, especially in HCT15
and LoVo cells, thereby showing a potential contribution
of p40phox in activation (Figure 5). In MOSER and LS180
cells, expression of p47phox is lower than in HCT116 cells,
however; it is higher in HCT15 cells. FdUrd significantly
induced p47phox expression in only LS180 and HCT116
cells, implicating the role of p40phox in the activation in
these cells (Figure 6). The logic behind these experiments
was profiling various colon cancer cell lines in terms of
their NOX metabolism. Experiments were done for all
NOX1 and NOX2 subunits, and variable expression levels
for each subunit were plotted as shown in Figures 4A, 5,
and 6. Among all subunits, only NOX2 cytosolic subunits,
p67phox, p40phox, and p47phox, show alteration in basal
and FdUrd-inducible levels. Although expression levels of
subunits are changed differently in colon cancer cell lines,

they all work for the activation of NOX2 enzyme. Therefore,
targeting this enzyme may enhance therapeutic approaches
in FdUrd-mediated cancer therapy.
CRC cell lines were genetically and epigenetically
characterized for mutations in oncogenes including KRAS,
BRAF, PIK3CA, PTEN, and TP53 (Ahmed et al., 2013).
HCT15, DLD-1, HCT116, LoVo, and SW480 cell lines
showed no mutations on BRAF and PTEN genes; however,
KRAS mutations were found in all lines. There were no
genetic differences in HCT15 and DLD-1 cells derived from
the same patient. In our study, these cells also show similar
patterns for NOX activity, protein, and mRNA expression
levels of p67phox (Figures 1, 4A, and 4B). PIK3CA
mutations were not found in LoVo and SW480 cell lines,
while DLD-1, HCT15, and HCT116 were characterized for
the mutations. Accordingly, basal p67phox expression was
higher in LoVo and SW480 compared to DLD-1, HCT15,
and HCT116 cells (Figure 4A).
Based on our results, the antitumor effects of FdUrd
appear to vary among colon cancer cell lines, reflecting
phenotypic heterogeneities. Each cell line shows different
expression levels of regulatory subunits and different levels
of NOX activity and apoptosis levels. Therefore, deeper
understanding of phenotypic features of each colon cancer
cell line could be essential to therapy of this deadly disease.
Acknowledgment
We thank Dr Franklin G. Berger for his guidance with
the experiments and analysis. We also thank the National
Cancer Institute (Grant CA44013) and the National
Institute of General Medical Sciences (Grant GM103336)
for the financial support of the research.

References
Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen
M, Lind GE, Lothe RA (2013). Epigenetic and genetic features
of 24 colon cancer cell lines. Oncogenesis 2: e71.
Alexandre J, Batteux F, Nicco C, Chéreau C, Laurent A, Guillevin
L, Weill B, Goldwasser F (2006). Accumulation of hydrogen
peroxide is an early and crucial step for paclitaxel-induced
cancer cell death both in vitro and in vivo. Int J Cancer 119:
41-48.
Altenhöfer S, Kleikers PW, Radermacher KA, Scheurer P, Rob
Hermans JJ, Schiffers P, Ho H, Wingler K, Schmidt HH (2012).
The NOX toolbox: validating the role of NADPH oxidases in
physiology and disease. Cell Mol Life Sci 69: 2327-2343.

Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch
O (2009). Improving outcome of chemotherapy of metastatic
breast cancer by docosahexaenoic acid: a phase II trial. Br J
Cancer 101: 1978-1985.
Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE
(1981). Heterogeneity of malignant cells from a human colonic
carcinoma. Cancer Res 41: 1751-1756.
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger
B, Starling N (2010). Colorectal cancer. Lancet 375: 1030-1047.
Danenberg PV (1977). Thymidylate synthetase – a target enzyme in
cancer chemotherapy. Biochim Biophys Acta 473: 73-92.

Bedard K, Krause KH (2007). The NOX family of ROS-generating
NADPH oxidases: physiology and pathophysiology. Physiol
Rev 87: 245-313.

de Anta JM, Mayo C, Solé F, Salido M, Espinet B, Corzo C, Petzold M,
Villa O, Serrano S, Real FX et al (2006). Methotrexate resistance
in vitro is achieved by a dynamic selectionprocess of tumor cell
variants emerging during treatment. Int J Cancer 119: 1607-1615.

Berger FG, Berger SH (2006). Thymidylate synthase as a
chemotherapeutic drug target: where are we after fifty years?
Cancer Biol Ther 5: 1238-1241.

Fidler IJ, Poste G (1985). The cellular heterogeneity of malignant
neoplasms. Implications for adjuvant chemotherapy. Semin
Oncol 12: 207-221.

193

ÖZER and WOOD BARBOUR / Turk J Biol
Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad
Ø (2004). Twelve colorectal cancer cell lines exhibit highly
variable growth and metastatic capacities in an orthotopic
model in nude mice. Eur J Cancer 40: 1593-1598.
Gallego MA, Ballot C, Kluza J, Hajji N, Martoriati A, Castera L,
Cuevas C, Formstecher P, Joseph B, Kroemer G et al (2008).
Overcoming chemoresistance of non-small cell lung carcinoma
through restoration of an AIF-dependent apoptotic pathway.
Oncogene 27: 1981-1992.
Hwang IT, Chung YM, Kim JJ, Chung JS, Kim BS, Kim HJ, Kim JS,
Yoo YD (2007). Drug resistance to 5-FU linked to reactive
oxygen species modulator 1. Biochem Biophys Res Commun
359: 304-310.
Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso
GF, Smith RAJ, Kinzler KW, Vogelstein B (2001). Ferredoxin
reductase affects p53-dependent, 5-fluorouracil–induced
apoptosis in colorectal cancer cells. Nature Medicine 7: 11111117.
Juhasz A, Ge Y, Markel S, Chiu A, Matsumoto L, van Balgooy J,
Roy K, Doroshow JH (2009). Expression of NADPH oxidase
homologues and accessory genes in human cancer cell lines,
tumours and adjacent normal tissues. Free Radic Res 43: 523532.
Krokan HE, Drablos F, Slupphaug G (2002). Uracil in DNA—
occurrence, consequences and repair. Oncogene 21: 89358948.
Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK (2008).
Oxidative stress is inherent in prostate cancer cells and is
required for aggressive phenotype. Cancer Res 68: 1777-1785.
Lambeth JD (2004). NOX enzymes and the biology of reactive
oxygen. Nat Rev Immunol 4: 181-189.
Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves
A, Levy E, Goldwasser F, Panis Y, Soubrane O et al (2005).
Controlling tumor growth by modulating endogenous
production of reactive oxygen species. Cancer Res 65: 948-956.
Leibovitz A, Stinson JC 3rd, McCombs WB, McCoy CE, Mazur
KC, Mabry ND (1976). Classification of human colorectal
adenocarcinoma cell lines. Cancer Res 36: 4562-4569.
Longley DB, Harkin DP, Johnston PG (2003). 5-Fluorouracil:
mechanisms of action and clinical strategies. Nat Rev Cancer
3: 330-338.
Lucas AS, O’Neil BH, Goldberg RM (2011). A decade of advances in
cytotoxic chemotherapy for metastatic colorectal cancer. Clin
Colorectal Cancer 10: 238-244.

O’Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D,
Halbherr T, Brennan J, Bookman MA, Hoffman J, Young
RC et al (1996). Phase I trial of buthionine sulfoximine in
combination with melphalan in patients with cancer. J Clin
Oncol 14: 249-256.
Ozer U, Barbour KW, Clinton SA, Berger FG (2015). Oxidative stress
and response to thymidylate synthase-targeted therapy. Mol
Pharmacol 88: 970-981.
Platell C, Ng S, O’Bichere A, Tebbutt N (2011). Changing
management and survival in patients with stage IV colorectal
cancer. Dis Colon Rectum 54: 214-219.
Ribas M, Masramon L, Aiza G, Capellà G, Miró R, Peinado MA
(2003). The structural nature of chromosomal instability in
colon cancer cells. FASEB J 17: 289-291.
Schmid J, Dussmann H, Boukes GJ, Flanagan L, Lindner AU,
O’Connor CL, Rehm M, Prehn JH, Huber HJ (2012). Systems
analysis of cancer cell heterogeneity in caspase-dependent
apoptosis subsequent to mitochondrial outer membrane
permeabilization. J Biol Chem 287: 41546-41559.
Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M,
Hirohashi S (2008). Genetic alteration of Keap1 confers
constitutive Nrf2 activation and resistance to chemotherapy in
gallbladder cancer. Gastroenterology 135: 1358-1368.
Siegel RL, Miller KD, Jernal A (2015). Cancer statistics. CA Cancer
J Clin 65: 5-29.
Soong R, Diasio RB (2005). Advances and challenges in
fluoropyrimidine pharmacogenomics and pharmacogenetics.
Pharmacogenomics 6: 835-847.
Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS,
Tan WL, Zeps N, Joseph D et al (2008). Prognostic significance
of thymidylate synthase, dihydropyrimidine dehydrogenase
and thymidine phosphorylase protein expression in colorectal
cancer patients treated with or without 5-fluorouracil-based
chemotherapy. Ann Oncol 19: 915-919.
Sotos GA, Grogan L, Allegra CJ (1994). Preclinical and clinical
aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev
20: 11-49.
Spears CP, Gustavsson BG, Berne M, Frosing R, Bernstein L, Hayes AA
(1988). Mechanisms of innate resistance to thymidylate synthase
inhibition after 5-fluorouracil. Cancer Res 48: 5894-5900.
Stein A, Atanackovic D, Bokemeyer C (2011). Current standards and
new trends in the primary treatment of colorectal cancer. Eur J
Cancer 47 Suppl 3: S312-S314.

McBain JA, Weese JL, Meisner LF, Wolberg WH, Willson JK (1984).
Establishment and characterization of human colorectal cancer
cell lines. Cancer Res 44: 5813-5821.

Ueta E, Yoneda K, Yamamoto T, Osaki T (1999). Manganese
superoxide dismutase negatively regulates the induction
of apoptosis by 5-fluorouracil, peplomycin and γ-rays in
squamous cell carcinoma cells. Jpn J Cancer Res 90: 555-564.

Milano G, Ferrero JM, Francois E (2004). Comparative pharmacology
of oral fluoropyrimidines: a focus on pharmacokinetics,
pharmacodynamics and pharmacomodulation. Br J Cancer 91:
613-617.

Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC,
Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988).
Genetic alterations during colorectal-tumor development. N
Engl J Med 319: 525-532.
Wyatt MD, Wilson DM (2009). Participation of DNA repair in the
response to 5-fluorouracil. Cell Mol Life Sci 66: 788-799.

194

